Semaglutide Approved for MASH in Japan, AASLD Maps Its Use

Two 2026 milestones mark the moment the second MASH drug went global. On June 19, 2026, Japan’s Ministry of Health, Labour and Welfare approved once-weekly semaglutide 2.4 mg (Wegovy) for MASH with moderate-to-advanced fibrosis, making it the first approved MASH therapy in Japan, and in August the AASLD practice guidance laid out exactly how US clinicians should select and monitor the patients it fits.

The approval rests on the phase 3 ESSENCE trial’s 72-week interim analysis in the first 800 of 1,197 randomized adults with biopsy-confirmed F2-F3 MASH. Semaglutide achieved MASH resolution without worsening fibrosis in 62.9 percent versus 34.3 percent on placebo, and fibrosis improvement without worsening MASH in 36.8 percent versus 22.4 percent, with weight loss near 10 to 11 percent against roughly 2 percent on placebo.

The Japan-specific story is worth its own paragraph because the approval broke new ground there. A prespecified Japanese subgroup of 116 participants, older and leaner than the trial average, published in The Journal of Gastroenterology (August 28, 2026), reproduced the resolution signal at 63.1 versus 36.8 percent, while the subgroup’s fibrosis estimate crossed the null, an honest limitation the analysis itself flags at a sample size never powered to stand alone.

The AASLD guidance is the operational layer US readers will actually meet. It defines candidate selection through noninvasive tests: VCTE liver stiffness of 8 to 15 kPa, MR elastography of 3.1 to 4.4 kPa, or an enhanced liver fibrosis score of 9.2 to 10.5, with a broader may-consider range above, and it names the exclusions, cirrhosis, pregnancy, and a personal or family history of medullary thyroid carcinoma or MEN2.

The response criteria close the monitoring loop. At 72 weeks, the guidance grades benefit as a 30 percent drop in VCTE stiffness, 20 percent in MRE, 17 U/L or 20 percent in ALT, or a 0.5-point fall in ELF, the same noninvasive numbers this site keeps translating, and it prescribes monitoring for gastrointestinal intolerance, gallbladder disease, pancreatitis, retinopathy progression, and lean-mass loss.

The combination-therapy question got a status update too. The guidance notes that combination with resmetirom has not been formally evaluated, while stable semaglutide dosing was accepted as a co-medication inside the resmetirom registrational trial, and the real-world data presented at EASL 2026 found added liver benefit with no clinically significant interactions, which leaves combination as promising practice, not yet policy.

The safety read is consistent across every layer of the story. Gastrointestinal effects, nausea, diarrhea, constipation, vomiting, were more common than placebo with no drug-induced liver injury cases confirmed, gallbladder events uncommon and mostly mild, no pancreatitis signal, and the Japanese subgroup’s pattern mirrored the whole, which is the profile expected from the class.

For a reader already on semaglutide for weight or diabetes, the MASH approval adds context rather than a change. The 2.4 mg dose and the F2-F3 fibrosis staging are the criteria that turn an obesity prescription into a liver one, and the liver-response checks at 72 weeks run on the same elastography and ELF numbers the clinic already monitors.

For a reader wondering whether to ask about it, the door is the staging pathway this site keeps describing. FIB-4 first, elastography second, and the 8-to-15 kPa window is where the drug conversation opens, with cirrhosis closing it, which means the reader’s first question at a visit is about staging, not the syringe.

The weight-independent question is the field’s live scientific edge. The trial delivered roughly 10 percent weight loss, and the translational commentary published in April 2026 weighs how much of the fibrosis benefit rides on the scale versus direct hepatic mechanisms, an unsettled question that matters for the leaner MASLD populations, including the Japanese subgroup, where less weight is available to lose.

None of this replaces the clinician. Eligibility, dosing, contraindication screening, and response monitoring are specialist decisions under the very documents described here, and no website converts an approval into a self-prescription, which is the boundary both the Japanese label and the AASLD guidance draw.

For a reader, the takeaway is that the MASH pharmacy now spans two drug classes on two continents, a liver-directed thyroid-receptor agonist and a systemic GLP-1, each carrying the same fine print: they work alongside diet and exercise, they are staged by the same noninvasive tests, and the plate remains the foundation neither drug replaces.

The cost-and-access reality belongs in the honest ledger. Approval is not availability, Japanese and US insurance pathways differ, and the ESSENCE part 2 outcomes readout expected in 2029 will decide whether the drug prevents the liver events the interim histology only promises, which is the distinction between a label and a proven mortality benefit.

For a reader, the week’s sentence is that MASH pharmacotherapy has become a globe-spanning standard with rules attached: stage the fibrosis, check the exclusions, start the diet and exercise that the label requires, and let the plate keep doing the base-layer work that every response metric in the guidance quietly depends on.

The lean-mass warning deserves its own paragraph because it connects to this month’s sarcopenia and frailty coverage. GLP-1 therapy sheds lean mass alongside fat, the AASLD guidance explicitly lists lean-mass loss among the monitored risks, and the reader combining the drug with resistance work and adequate protein is protecting the muscle the frailty literature tied to mortality, which makes the strength habit part of the drug’s proper use, not an optional extra.